Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Open accessThe DOI matches its Crossref record; 224 of the 227 references it cites were found in a registry or an index.
Abstract
Anti-cancer antibody-drug conjugates (ADCs) aim to expand the therapeutic index of traditional chemotherapy by employing the targeting specificity of monoclonal antibodies (mAbs) to increase the efficiency of the delivery of potent cytotoxic agents to malignant cells. In the past three years, the number of ADCs approved by the Food and Drug Administration (FDA) has tripled. Although several ADCs have demonstrated sufficient efficacy and safety to warrant FDA approval, the clinical use of all ADCs leads to substantial toxicity in treated patients, and many ADCs have failed during clinical development due to their unacceptable toxicity profiles. Analysis of the clinical data has demonstrated that dose-limiting toxicities (DLTs) are often shared by different ADCs that deliver the same cytotoxic payload, independent of the antigen that is targeted and/or the type of cancer that is treated. DLTs are commonly associated with cells and tissues that do not express the targeted antigen (i.e., off-target toxicity), and often limit ADC dosage to levels below those required for optimal anti-cancer effects. In this manuscript, we review the fundamental mechanisms contributing to ADC toxicity, we summarize common ADC treatment-related adverse events, and we discuss several approaches to mitigating ADC toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Bispecific ADCs have increased selectivity and internalization, as well as may limit ADC binding to normal tissue, reducing on-target off-tumor toxicity5,230.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [230]
Experimental — accuracy not yet measuredIn the citing paper
“their substantial toxicity (primarily affecting the bone marrow) must be considered.69 70”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–224 of 224
Effect of Linker-Drug Properties and Conjugation Site on the Physical Stability of ADCs
Mills, B. J., Kruger, T. M., Bruncko, M., Zhang, X., & Jameel, F. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.01.029 · Cited by 29
Lobo, E. D., Soda, D. M., & Balthasar, J. P. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10432 · Cited by 28
Self-citationManiecki, M. B., Hasle, H., Bendix, K., & Møller, H. J. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.01.025 · Cited by 28
Shah, D. K., & Balthasar, J. P. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.01.038 · Cited by 25
Self-citationThompson, J. A., Motzer, R. J., Molina, A. M., Choueiri, T. K., Heath, E. I., Kollmannsberger, C., Redman, B. G., Sangha, R. S., Ernst, D. S., Пили, Р., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.2503 · Cited by 25
Doi, T., Iwata, H., Tsurutani, J., Takahashi, S., Park, H., Redfern, C. H., Shitara, K., Shimizu, C., Taniguchi, H., Iwasa, T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.108 · Cited by 25
Mita, M. M., Ricart, A. D., Mita, A. C., Patnaik, A., Sarantopoulos, J., Sankhala, K. K., Fram, R. J., Qin, A., Watermill, J., & Tolcher, A. W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3062 · Cited by 24
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0804 · Cited by 22
Self-citationYamaguchi, A., Anami, Y., Ha, S. Y. Y., Roeder, T. J., Xiong, W., Lee, J., Ueno, N. T., Zhang, N., An, Z., & Tsuchikama, K. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116013 · Cited by 21
Bordeau, B. M., Abuqayyas, L., Nguyen, T. D., Chen, P., & Balthasar, J. P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.837744 · Cited by 18
Self-citationBorghaei, H., O’Malley, D. M., Seward, S. M., Bauer, T. M., Perez, R. P., Oza, A. M., Jeong, W., Michenzie, M. F., Kirby, M. W., Chandorkar, G., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.5558 · Cited by 16
Use of trastuzumab in treating breast cancer during pregnancy: a systematic review and meta-analysis
Xia, L.-Y., Hu, Q.-L., & Zhou, Q. (2021) · BMC Women s Health · doi:10.1186/s12905-021-01301-9 · Cited by 16
Impact of charge patches on tumor disposition and biodistribution of therapeutic antibodies
Stüber, J. C., Rechberger, K. F., Miladinović, S. M., Pöschinger, T., Zimmermann, T., Villenave, R., Eigenmann, M. J., Kraft, T. E., Shah, D. K., Kettenberger, H., et al. (2022) · AAPS Open · doi:10.1186/s41120-021-00048-9 · Cited by 16
Chen, P., Bordeau, B. M., Zhang, Y., & Balthasar, J. P. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0192 · Cited by 14
Self-citationGarcía-Corbacho, J., Spira, A. I., Boni, V., Feliú, J., Middleton, M. R., Burris, H. A., Weaver, A. M., Will, M., Harding, J. J., Meric‐Bernstam, F., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx367.055 · Cited by 13
Singh, R., Reid, E. E., Harris, L., Salomon, P. L., Miller, M. L., Chari, R. V. J., & Keating, T. A. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00675 · Cited by 12
UPLC-based assay to assess the hydrophobicity of Antibody-Drug Conjugate (ADC) payloads
Pysz, I., Jackson, P. J. M., Barlow, D. J., Rahman, K. M., & Thurston, D. E. (2020) · Journal of Chromatography B · doi:10.1016/j.jchromb.2020.122075 · Cited by 12
Lansita, J. A., Burke, J. M., Apgar, J. F., & Mounho-Zamora, B. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1742-y · Cited by 10
Lobo, E. D., & Balthasar, J. P. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20422 · Cited by 9
Self-citationSagert, J. G., West, J., Wong, C., Desnoyers, L., Vasiljeva, O. S., Richardson, J. H., Polu, K. R., & Lowman, H. B. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-2665 · Cited by 8
Liu, B., Shen, J., Wang, Y., Jing, C., Saha, S., Rangan, V. S., Richardson, J. H., Liu, Y., Boulé, S., Lucas, J., et al. (2020) · European Journal of Cancer · doi:10.1016/s0959-8049(20)31104-7 · Cited by 5
Sandall, S. L., Mason, M. L., Olson, D. J., Mazahreh, R. C., Pires, T., Sahetya, D., Westendorf, L., Leiske, C. I., Schimpf, B. A., Nguyen, L. T., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-2688 · Cited by 4
Frontiers in Anti-Cancer Drug Discovery
(2013) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/97816080580821130201 · Cited by 2
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2024) · doi:10.1158/1535-7163.c.6908531 · Cited by 1
Self-citation
Research works printed but not linked: 5
- GlaxoSmithKline (2023, January 17). GSK Provides an Update on Blenrep (Belantamab Mafodotin-Blmf) US Marketing Authorisation. Available online: https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-blenrep-us-marketing-authorisation/.
- Actor, J.K. (2012). Elsevier’s Integrated Review Immunology and Microbiology, W.B. Saunders. [2nd ed.].
- Herrera, 2017, A Phase I Study of the Anti-CD79b THIOMABTM-Drug Conjugate DCDS0780A in Patients (pts) with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (B-NHL), Blood, 130, 4129
- Damelin, M. (2018). Innovations for Next-Generation Antibody-Drug Conjugates, Springer International Publishing. · DOI
- Damelin, M. (2018). Innovations for Next-Generation Antibody-Drug Conjugates, Springer International Publishing. · DOI
Cited by
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
Tarantino, P., Ricciuti, B., Pradhan, S. M., & Tolaney, S. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00783-w · Cited by 269
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M., & de Vries, E. G. E. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0708 · Cited by 254
A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy
Riccardi, F., Dal Bo, M., Macor, P., & Toffoli, G. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1274088 · Cited by 188
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01521-5 · Cited by 162
Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response
Chang, H. L., Schwettmann, B., McArthur, H. L., & Chan, I. S. (2023) · Journal of Clinical Investigation · doi:10.1172/jci172156 · Cited by 136
Metadata
- Authors
- Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P.
- Affiliations
- University at Buffalo, State University of New York (US)
- Corresponding author
- Balthasar, Joseph P.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2023-01-24
- Volume
- 15
- Issue
- 3
- Pages
- 713
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC9913659
- OpenAlex
- W4317932204
- Cited by
- 441
- References
- 227
- Citations by year
- 2026: 150 · 2025: 172 · 2024: 99 · 2023: 20
- FWCI
- 18.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA246785, CA256928)
- University at Buffalo Center for Protein Therapeutics (CA246785, CA256928)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- antibody-drug conjugates, off-target toxicity, dose-limiting toxicity, treatment-related adverse events, toxicity mechanisms, tolerability, cytotoxic payloads, monoclonal antibodies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.